In a rather positive development amid the raging pandemic, Bharat Biotech has begun the human trials of COVAXIN, India’s first indigenous vaccine candidate for COVID, on three subjects, and all of them have tolerated it well, so far.
In a rather positive development amid the raging pandemic, Bharat Biotech has begun the human trials of COVAXIN, India’s first indigenous vaccine candidate for COVID, on three subjects, and all of them have tolerated it well, so far.
“Human trial with Corona vaccine (COVAXIN) of Bharat Biotech started at PGIMS, Rohtak today. Three subjects were enrolled today. All have tolerated the vaccine very well. There were no adverse effects,” tweeted Haryana Health Minister Anil Vij on Friday.
Over the past 10 days, the Post Graduate Institute of Medical Sciences, Rohtak, has registered nearly 100 people wanting to be a part of the study that was approved by the DCGI earlier this week.
The Hyderabad-based pharma collaborated with the nation's apex medical body ICMR and National Institute of Virology, Pune, to develop the vaccine candidate. It was developed at Bharat Biotech's BSL-3 (Bio-Safety Level 3) high containment facility, which is located in the Genome Valley.
Meanwhile, Ahmedabad-based pharmaceutical giant Zydus Cadila, the second firm to come up with an indigenous coronavirus vaccine candidate, has also begun the crucial phase I and II of human trials after receiving nod from the DGCI. However, the company had stated that the completion of phase I and II trials may take up to three months.
“Human trial with Corona vaccine (COVAXIN) of Bharat Biotech started at PGIMS, Rohtak today. Three subjects were enrolled today. All have tolerated the vaccine very well. There were no adverse effects,” tweeted Haryana Health Minister Anil Vij on Friday.
Over the past 10 days, the Post Graduate Institute of Medical Sciences, Rohtak, has registered nearly 100 people wanting to be a part of the study that was approved by the DCGI earlier this week.
The Hyderabad-based pharma collaborated with the nation's apex medical body ICMR and National Institute of Virology, Pune, to develop the vaccine candidate. It was developed at Bharat Biotech's BSL-3 (Bio-Safety Level 3) high containment facility, which is located in the Genome Valley.
Meanwhile, Ahmedabad-based pharmaceutical giant Zydus Cadila, the second firm to come up with an indigenous coronavirus vaccine candidate, has also begun the crucial phase I and II of human trials after receiving nod from the DGCI. However, the company had stated that the completion of phase I and II trials may take up to three months.